Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR T are limited....

Descripción completa

Detalles Bibliográficos
Autores principales: Zurko, Joanna, Ramdial, Jeremy, Shadman, Mazyar, Ahmed, Sairah, Szabo, Aniko, Iovino, Lorenzo, Tomas, Ana Alarcon, Sauter, Craig, Perales, Miguel-Angel, Shah, Nirav. N., Acharya, Utkarsh H., Jacobson, Caron, Soiffer, Robert J., Wang, Trent, Komanduri, Krishna V., Jaglowski, Samantha, Kittai, Adam S., Denlinger, Nathan, Iqbal, Madiha, Kharfan-Dabaja, Mohamed A., Ayala, Ernesto, Chavez, Julio, Jain, Michael, Locke, Frederick L., Samara, Yazeed, Budde, Lihua E., Mei, Matthew G., Pia, Alexandra Della, Feldman, Tatyana, Ahmed, Nausheen, Jacobs, Ryan, Ghosh, Nilanjan, Dholaria, Bhagirathbhai, Oluwole, Olalekan O., Hess, Brian, Hassan, Ayesha, Kenkre, Vaishalee P., Reagan, Patrick, Awan, Farrukh, Nieto, Yago, Hamadani, Mehdi, Herrera, Alex F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827150/
https://www.ncbi.nlm.nih.gov/pubmed/35833303
http://dx.doi.org/10.3324/haematol.2022.281242

Ejemplares similares

Ejemplares similares